Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-11-06

Lead Sponsor: Royal Marsden NHS Foundation Trust

Registration Number: NCT00004237

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004907

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004181

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy in Treating Women With Resected Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: Institute of Cancer Research, United Kingdom

Registration Number: NCT00033683

Locations: 🇬🇧
St. Georges Hospital Medical School, London, England, United Kingdom
🇬🇧
Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

and more 66 locations

Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004896

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin
Drug: leucovorin
Drug: methotrexate
Drug: vincristine

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 56

Registration Number: NCT00041132

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Multiple Myeloma and Malignant Plasma Cell Neoplasms
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: cyclophosphamide
Radiation: TBI

First Posted Date: 2003-01-27

Last Posted Date: 2012-10-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 72

Registration Number: NCT00005622

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2012-10-02

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT00007904

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
UH-LUICC, Mentor, Ohio, United States
🇺🇸
UH-Chagrin Highlands, Orange Village, Ohio, United States

Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 32

Registration Number: NCT00039351

Locations: 🇳🇱
Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇧🇪
Ziekenhuis Network Antwerpen Middelheim, Antwerp, Belgium
🇧🇪
Centre Hospitalier Universitaire Brugmann, Brussels, Belgium

and more 14 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 400

Registration Number: NCT00003215

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy